Abstract LDL, VLDL and other members of the low-density lipoparticles (LLPs) enter cells through a large family of receptors. The actual receptor ligand(s) in apolipoprotein B100, one of the main proteins of LLP, remain(s) unknown. The objective of this study was to identify true receptor ligand(s) in apo B100, a molecule of 4563 residues. Apo B100 contains 33 analogues of Cardin-Weintraub arginine/lysine-based receptor ligand motifs and shares key lysine motifs and sequence similarity with the LDL receptor-associated protein, MESD, and heat shock proteins. Eleven FITC-labeled synthetic peptides of 21-42 residues, with at least one ligand, were tested for binding and internalization using HeLa cells. All peptides bind but display different binding capacities and patterns. Peptides B0013, B0582, B2366, and B2932 mediate endocytosis and appear in distinct sites in the cytoplasm. B0708 and B3181 bind and remain on the cell surface as aggregates/clusters. Peptides B3119 (Site A) and B3347 (Site B), the putative ligands, showed low binding and no cell entry capacity. Apo B100 regions in this study share similarities with related proteins of known function including chaperone proteins and Apo BEC stimulating protein, and not directly related proteins, e.g., the DNA-binding domain of interferon regulatory factors, MSX2-interacting protein, and snake venom Zinc metalloproteinase-disintegrin-like proteins.
Introduction
It is generally accepted that the main physiological role of apo B100 in low density lipoprotein particles (LLPs)-very low-density lipoproteins (VLDL), intermediate density lipoproteins (IDL) and low density lipoprotein (LDL)-is transport and intracellular delivery of cholesterol, cholesteryl ester, triglycerides, phospholipids, and other low molecular weight compounds, such as vitamins, hormones (sterols, retinol and tocopherols) [1, 2] . LLPs are also involved in the transport of a great variety of smaller proteins including multiple copies of apolipoprotein E (apo E) and other apolipoproteins such as apo C-I, -II, -III, A-I, -II, -IV, and M [3] [4] [5] . Accrued evidence supports a model in which apo B100 and apo E achieve endocytosis via membrane receptors [6] [7] [8] .
Apo B100 is a member of the large lipid transfer protein (LLTP) superfamily that includes microsomal triglyceride transfer protein (MTTP), vigilin, vitellogenins, and insect lipophorins [9] [10] [11] . Non-apo B100 LLTPs are known to have multiple roles, including protein-protein interactions in immune response [12] [13] [14] and mRNA binding [15] [16] [17] . Apo B100 is a massive, semi-hydrophobic molecule of 4536 amino acids and, like other LLTPs, contains a variety of short sequence motifs indicative of potential function [7, 8, 18, 19] .
Other functions of apo B100 are supported by several reports implying a role for LDL and VLDL in cell signaling pathways [20] [21] [22] [23] [24] . The strongest evidence that LLPs have functions beyond lipid transport is based on LDL's ability to bind nucleic acids and efficiently transfect cells in culture and the rat in vivo [25, 26] . LDL's capacity to bind RNA is likely based on 11 Gly-X-X-Gly motifs in the apo B100 sequence. These motifs are characteristic of RNA-binding proteins [27, 28] . In addition, the N-terminal 100-residue sequence of apo B100 contains several motifs also present in the DNA-binding domains of the interferon regulatory factors, IRFs [21, 25] . Two synthetic peptides covering residues 13 thru 94 were shown to bind plasmid DNA using electrophoresis mobility shift assays (EMSA) and to deliver it to the nucleus of HeLa cells in culture [25, 26] . Two other synthetic peptides spanning the sequence between 3313 Asp-Thr 3401 were shown to bind DNA but did not bind or enter the cell. The latter sequence shares some motifs with known dengue helicases. The region between 3804 Ser-Lys 4006 contains several motifs also found in the signal transducer kinases, e.g. JAK1 and JAK2 [20] . Kinase activity was shown experimentally using highly purified preparation of LDL [20] .
Endocytosis of LLPs is mediated by a large gene family of receptors, low-density lipoprotein receptor-related proteins (LRPs), with quite extensive set of ligand-binding modules that recognize a variety of ligand sequences [29] [30] [31] . The diversity of the potential ligands provokes the questionwhat is/are the real LDL receptor ligand(s) on apo B100? The LDL receptor and glycosaminoglycan (GAG) ligand motifs occur in lysine/arginine-rich clusters, XBBBXXBX (Type I), XBBXBX (Type II), and ΨBΨXB (Type III), where X is any amino acid and Ψ is a non-polar residue [32] [33] [34] . These are known as Cardin-Weintraub (C-W) motifs [34] . Other elements that may be involved in forming clathrin-coated vesicles, i.e. endocytic motifs, have not been confirmed for either apo E or apo B100. Apo 
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, Type III motifs, the critical residues for high affinity binding to LDL B/E receptor are lysine residues in positions 143 and 146 of the Type II ligand motif [35, 36] . Motif LRK that appears twice in tandem in Apo E is an analogue of motifs VKK and WKK in RAP (alpha-2-macrogolublin receptor-associated protein; AMRP_HUMAN; P3-533), an intracellular chaperone for the LDL receptor and related receptor proteins with 3D structure established using X-ray crystallography [37] . There are other motifs in apo B100 and apo E that are similar to the motifs in heat shock proteins, known chaperones for the LDLR family of proteins [29] [30] [31] . Apo E also contains two potential endocytic motifs, [38, 39] . Apo E has been reported to bind several members of the LDL supergene family of receptors [35, 40] and highly sulfated GAGs, such as heparin and heparan sulfate [34] . LLPs, including LDL, are removed from plasma using GAGs affinity chromatography in a clinical application [41] .
Published reports suggest that the apo B100 molecule contains several potential receptor ligand analogs. Two sites in apo B100 sequence were identified as potential receptor ligands based on their similarity to the apo E ligand [7, 8, 19] . Site A contains Type II ligand motif, 3145 VKAQYKKNKHRHS 3157 while Site B, 3351 YKLEGT-TRLTRKRGLKL 3367 , possesses an arginine-rich, Type I motif. Hospattankar et al. [42] , proposed that multiple regions rich in positive charged residues in apo B100 have potential for binding to LDL receptors. Seven heparinbinding sites in apo B100 were identified using proteolytic digestion methods [43] . Sites encompassing 3134 Leu-Lys 3209 (overlaps with Site A), and 3356 Thr-Ala 3489 (partially overlaps with Site B), were found to have high affinity to heparin and were also considered to possess LDL receptor binding capacity. In a separate report [44] , four murine monoclonal antibodies, Mabs 2A, 5A, 7A, and 9A, to epitopes in three different regions of apo B100 were shown to reduce LDL interaction with the receptor by "up to 95%". These apo B100 regions are defined as follows: 5A, 1480 Asp-Val 1693 ; 2A and 7A, 2152 Gln-Asn 2377 ; and 9A, 2657 Gln-Lys 3248 . The goal of the present study was to identify regions in the apo B100 sequence with lysine-based motifs that may be involved in binding HeLa cells. Presence of membrane LDL receptors by HeLa cells is well known and their expression can be manipulated in various ways including nutrient reduction and/or including statins in the medium [45] . Analyzing apo B100 sequence for content of Type I-III LDL receptor ligands and short lysine-based receptor ligand motifs of RAP
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and heat shock proteins [46] , we identified approximately sixty potential receptor binding sites and a plethora of endocytic motifs. Fluorescence-labeled (FITC) synthetic peptides of eleven regions of apo B100 with at least one potential receptor ligand and some with candidate internalization motifs were used to assess their interaction with HeLa cells, i.e. binding, internalization and possible nuclear translocation. In this report, we qualitatively describe cell-binding properties of these peptides, along with our insights into other possible functions of the selected regions of apo B100.
Materials and Methods
Sequences included in this study were obtained from NIH NCBI PUBMED Protein and Structure databases. Synthetic peptides used in these studies, shown in Table 1 , are based on regions in the apo B100 which contain a candidate LDL receptor ligand motif and share sequence similarity with known functional regions in other proteins.
Chemicals
All cell culture media, PBS (Media Tech, Inc.), fetal bovine serum, penicillin G-sodium, streptomycin sulfate, Trypsin, and Corning Costar 12-well culture plates were purchased from Thermo-Fisher Scientific, Inc. Mevastatin and all other reagents used in this study were obtained from SigmaAldrich, Inc.
Water of 18 MΩ cm resistivity (Barnstead, E-pure water purification system) was used throughout this project.
Fluorescence-Labeled Peptides
Fluorescein Isothiocyanate (FITC)-labeled synthetic peptides of selected regions of the apo E and apo B100 molecules (Table 1) were obtained from NEO Group, Inc. Cambridge, MA. All synthetic peptides were of 95% or greater purity assessed by HPLC analysis. Lyophilized peptides were solubilized prior to use in PBS-5 mM MgCl 2 to yield 1 mg/mL. Peptide solutions were then stored in liquid N 2 .
Cells
As reported previously [26] , HeLa cells (human cervix epithelial adenocarcinoma cell line, CCL-2™) were obtained from American Type Culture Collection (ATCC). Cells were stored in a liquid N 2 until needed. Cells were then thawed, seeded and propagated according to ATCC protocols in DMEM supplemented with 10% FBS, 100 units penicillin G-sodium and 100 units/mL streptomycin sulfate (DMEM -P/S -FBS) at 37 °C in an atmosphere of 5% CO 2 .
LDL Purification
Highly purified preparations of low-density lipoproteins were obtained from single donor human plasma with sodium-EDTA added at time of collection (Innovative Research Corporation, Novi, MI). LDL was purified from human plasma by sequential ultracentrifugation in NaBr solutions within 1.019-1.05 g/mL density range using methods described previously [26] . LDL preparations were then dialyzed in PBS-5 mM MgCl 2 , frozen drop-wise, and stored in liquid N 2 , in about 200 µL aliquots until needed. Purity was assessed using Coomassie Brilliant Blue-stained, native 0.5% agarose gel electrophoresis.
CM-DiI Labeling of LDL
Purified human LDL, isolated as described above, was covalently labeled using CM-DiI. Briefly, 250 µL of ethanol was added to the vial containing 50 µg CM-DiI (C-7000), a thiolreactive fluorescence compound from Invitrogen, Inc., to make a stock solution. Next, 1 µL of CM-DiI stock solution was added to 1 mg (by protein) of purified LDL in 1 mL of PBS-5 mM MgCl 2 . The reaction mixture was allowed to stand for 30 min at ambient temperature, then dialyzed overnight in 1 L PBS-MgCl 2 with three changes of the buffer.
FITC-Synthetic Peptide Cell Binding
In cell binding/endocytosis experiments HeLa cells at ~ 70% confluence were pre-conditioned by incubating overnight in DMEM -P/S -3% FBS medium containing 1.0 µM Mevastatin [47, 48] . Cells were rinsed thrice with 3 mL PBS-5 mM MgCl 2 . Peptide-binding assays were performed at 37 °C for 30 min in 0.5 mL solution containing 440 µL PBS-5 mM MgCl 2 plus 60 µL the FITC-synthetic peptide. The assay solution was then removed, cells were rinsed as before, then incubated at ambient for 10 min in 1 mL 10% formaldehyde in PBS-MgCl 2 . Cells were next rinsed as previously and images were then obtained.
Dual Label Experiments
In these assays FITC-labeled apo B synthetic peptides were used in combination with CM-DiI labeled purified LDL. HeLa cells were preconditioned as before, then incubated at 37 °C for 30 min in medium containing 340 µL PBS with 5 mM MgCl 2 , plus approximately 300 µg labeled-LDL and 60 µg labeled apo B peptide, then rinsed thrice with buffer, fixed in 1% formaldehyde; 1 s exposure images were next obtained at ×50 and ×630 magnification.
Fluorescence Microscopy
Microscopy was performed using a Zeiss Axiovert 25 equipped with Zeiss objectives, FITC/GFP (Zeiss HQ470/40× and HQ525/50 m) and red (Chroma AT540/25× and AT605/55 m) filter cubes, and a motorized x, y, z stage from Prior Scientific, Inc., Rockland, MA. Images were captured thru a 0.5× C-mount adapter using an Optronics Microfire CCD camera and Picture Frame software as described previously [26] . FITC signal intensity obtained for ×50 view field was used to assess cell binding and images obtained at ×630 magnification were used to assess cell entry and location. For further processing, all green fluorescence fluorescence images. All synthetic peptides used in the present study were shown to bind HeLa cells, but with distinct avidities as well as different cell interaction pattern ( Fig. 1 ; Table 2 ).
Cell Binding Capacity
Fluorescence images in Fig. 1 , captured at ×50 magnification and 1 s exposure, were used to assess cell binding efficiency with ImageJ algorithms. Cell binding efficiency, i.e. number of cells emitting signal, number of signal loci per cell, signal density per cell, and signal density per locus were determined (see Sect. 2). Forty-four bright field images were captured displaying 127,033 cells in toto, with 2757 cells per view field on average. Multiple corresponding fluorescence images for each peptide and different magnifications were also obtained, except for peptides B0582 and B3181. For these peptides, green fluorescence images at ×50 were obtained at 100 and 173 ms exposures, as 1 s exposure times completely overwhelmed the view field. Images were then normalized to 1 s exposures. Digital data was generated by analysis of multiple view field images, at least four for each peptide.
Analysis of the emitted signal for cells viewed at ×50 magnification is shown in Table 2 . Results in column "percent of total signal area per cell area," show that peptides Table 1 were captured at ×50 magnification at 100 ms exposures using an Optronics Microfire CCD camera and Picture Frame software as described in Sect. 2. Brightness and contrast algorithms in ImageJ were used to enhance images B0013, B0708, and B2366 bind to approximately 11-13% of the total cell area as determined using corresponding bright field images. Signal for B2932 and B3181 is seen for about 4.5% of the cell area; B0575 and B0582 signal represent about 2.3%; B0055, B3119 (Site A) and B3347 (Site B) signal corresponds to an average of 1.7%; and, B2054 signal emits from less than 1% of cell area. A different binding pattern is observed: an average of 1.5 loci emitting signal per cell was seen with B0013; while B0708 and B2366 signal was present on about half of the cells (0.47 loci/cell To assess cell entry and intracellular localization, images for each peptide were also obtained at ×630 magnification. Overlay images of green fluorescence and corresponding bright field images were developed and are shown in Fig. 2 . Enlarged regions of overlay images for each peptide displaying individual cells with associated peptide signal are shown under the corresponding frames in Fig. 2 .
Sequence comparisons of apo B100 peptides to proteins with similar short sequence motifs that may provide insights into other potential functions of the selected regions of apo B100 are presented in Tables 3, 4 , 5, 6, 7, 8 and 9. Sequence similarity is based on the location of potential receptor ligand motifs as well as coincidence of basic residues proximal to the ligand and/or presence of other motifs of known function, e.g. di-lysine and a lysine/arginine NLS, a bipartite NLS. Table 3 . RAP is a resident endoplasmic reticulum protein and an intracellular chaperone for the LDL and VLDL receptors (LDLR and VLDLR, respectively), and 15 related receptors, such as LDLR related proteins (LRPs) and alpha-2-macroglobulin receptor [37] . All three domains in RAP (RAP1d, RAP2d, and RAP3d) were shown to have high binding affinity for LRP [50] . Lysine residues 0060 in motifs WKKLK and 0191 in LKEKL of RAP Domains 1 and 2, respectively, were shown experimentally to bind LDLR related protein 1 (LRP-1) with high affinity [51] . In RAP3d, residues Lys and DKL at 0137 in RAP2d; and, EKH at 0256 in RAP3d; these motifs are involved in binding to ligand adhesion modules, LA3-4 of the LDLR and CR5-6 of LRP-1 [50] [51] [52] . Motif VKK at positions 0305-0306 was also confirmed as a ligand for binding LRP [53] .
Included in Table 3 are sequences of regions in MESD, mesoderm development protein and an LDLR chaperone [54] , and in other heat shock proteins that are known to bind LDLR family [30] , although mostly via unknown mechanisms. Potential lysine-based receptor ligand motifs in these proteins are similar to motifs in the apo B100 sequence. Motifs in the B0013 region occur in HSPs BAB15121 and NP_001017963. We identify B0013 motif TRFKHLRKY-TYNY as a strong candidate for binding to LDLR and perhaps other LRPs. Although B0055 sequence shares lysine motifs with MESD and other HSP sequences, the motif KALLKKTK has not been shown to have the same HeLa cell binding capacity as B0013. Renditions of sequence LKKLVKEVLKESQ that is in B0575 and B0582 are in the HSP sequences shown in Table 3 . B0708 contains motif TKDDKHEQD which appears as AKIEKHNHYQ in RAP. Motif SVEKLIKDLKSKE of B0708 shares similarities with SKEKNKTKQDKG of MESD and KDKALKDK-IEK in HSP NP_003290. B2054 that shows low level HeLa binding capacity shares motifs ERNRQT and RKYRAALG with HSP NP_003290, which contains renditions EKTKES and KIEKAVVS, respectively. B2932 has three motifs that are similar to those in HSPs shown, INS, YESGS, and NFSKLE. B2932 was selected for this study based on its similarity to B0013, the potential cell binding motif is SKHLR. This peptide shows high binding capacity that may involve motifs NKI, SKH, and SKL; the latter is in the HSP. B3119 is a lysine-rich peptide and shares some similarity with HSP NP_003290. Renditions of sequence TKIKFDKY-KAEKSQ, carboxyl end of B3181, are in RAP, HSPs, and MESD. The lysine-rich region in the MESD sequence was shown to be located in a loop on the surface of the molecule (2KGL-CN3D) and may be the ligand region for the LDLR [54] . High sequence similarity between B3181 and these chaperone proteins supports a role for this region of apo B100 in binding to the LDLR. Although the motif RLTRKR-GLK, Type I C-W, in B3347 is very similar to RKLRKR-LLR in apo E and to KVIRKKLVRK in HSP NP_003290, it differst from these sequences in that it lacks the LRK of apo E, which is present in the HSP as IRK, VRK, and IKK. This deficiency may attribute to its poor binding capacity to HeLa cells.
Similarity of our synthetic peptide sequences to RAP, MESD, and heat shock proteins suggests that apo B100 contains several potential receptor ligands. 
Assessment of B3181 HeLa Cell Interaction
Total ISD and ISD per cell values for B3181 are significantly different (P < 0.05) compared to all other peptides except B0582. We identify B3181 as the principal candidate for potential receptor ligand based on its similarity to RAP, MESD, and other heat shock proteins, as discussed above. Interestingly, this region of apo B100 is located between Sites A and B, the putative ligand regions for the LDLR. Large, high intensity clusters of FITC signal appear throughout the view field of B3181 images in Fig. 2 . Extracellular space appears to be devoid of signal.
Assessment of B0013/B0055 HeLa Cell Interaction
Apo B100 N-terminal region spanning residues 0013 Lys-Phe
0094
, which includes peptides B0013 and B0055, has the capacity to bind plasmid DNA and deliver it to the cell nucleus [25, 26] . In the present study, experiments were designed to assess the role that each sequence may have in to binding HeLa cells and negotiating entry. Results in Fig. 2 show B0013 binds to most cells in view field; signal clusters and multiple fluorescence points are seen in the top frame. Red arrow in lower frame with enlarged region denotes signal that appears to be in the cytoplasm. In bright field images some clusters appear as dull golden speckles on the cell surface. A scatter of weak signal is apparent in the extracellular space with some faint points on the individual cell filopodia. Integrated density in some loci is relatively strong as indicated by red arrow in the enlarged frame, although average ISD per locus is the lowest for this peptide (Table 2) due to many faint loci in the view field.
In Fig. 2 , top row, column 2, B0055 signal is seen only at discrete loci on about 12% of the cells in the view field, as multiple fluorescence points and brighter clusters; the image of an enlarged region shows mostly the faint signal.
LDL Receptor Binding: Similarity of B0013 and B0055 to RAP Domain 2
Similarities between the apo B100 sequence and RAP2d are highlighted in Table 3 
Potential Function: Similarity of B0013 and B0055 to DNA-Binding Domain of IRF Proteins
The similarity between the first 110 residues of the N-terminus of apo B100 and the DNA-binding domain of IRF 9 was reported previously [21, 25] . The apo B100 region, 0013 Glu-Arg 0100 contains motifs common to the DNA-binding domains in IRF proteins (Table 4 ). Sequence alignment is based on a putative NLS cluster in the N-termini of IRF proteins, a polar amino acid stretch, and a proline-glycine dipeptide, followed by motifs that are analogous to RSA-TRINCK, SFILK, KALLK, and KKTKNSEEF in apo B100. This sequence comparison shows that the N-terminus of apo B100 is most like the DNA-binding domains of IRFs 9, 8 and 4.
The first basic residue cluster in apo B100, 0013 KDATRFKHLRK, is similar to RARCTRKLR, an NLS motif in IRF9; and, in apo B100 it appears to be a new potential receptor ligand motif. An endocytic motif, FKHL, occurs in this sequence. An extensive sequence of polar residues, YTSYNYEAESS, in apo B100 is perhaps analogous to sequence NWVVEQVESGQ in IRF9. In apo B100, this stretch is followed by 0035 GVPG (included in B0013), a motif characteristic of the heterogeneous nuclear ribonucleoprotein K, the K homology (KH) motif [27, 28] . The proline-glycine dipeptide is also common in a similar location in most DNA-binding domains of IRF proteins. Renditions of the KH motif appear in IRF4 in the sequence 0005 GGGRGGEFG and in IRF9 as 0072 GDTG. The B100 sequence 0043 RSATRINCK that follows is analogous to KSIFRIPWK, a motif conserved in IRFs 4, 7, 8 and 9. The carboxyl region of apo B100 DNA-binding domain sequence, 0059 Leu-Leu 0105 [26] , contains motifs present in IRF proteins 4, 8 and 9; for example, 0060 CSFILKTS of B0055 occurs in tandem in IRFs, as DAALFK in 4, ASIFK in 8, and AALFK in 9. The KTS motif in B0055 may function as an analogue of a potential anti-integrin, non-RGD adhesion motif [55] . Another motif in B0055 is KALLK, which appears as KTRLR in IRFs 4, 8 and 9. Next, apo B100 sequence 0088 TKNSEEFAAAMSR is an analogue of NKSNDFEELVER in IRF 4 and 0089 NKSSEFKEVPER in IRF 9. The B sequence FAAAM may be an endopeptidase, i.e. neutrophil elastase, cleavage site [56] . Also, B0055 contains an endocytic motif, 0080 EGKALL, and a true Type II receptor ligand motif, 0085 LKKTKN that does not impart [57] , are also in proposed IRF-like DNA-binding regions of apo B100.
Assessment of B0708 HeLa Cell Binding Capacity
The contrast-enhanced, high magnification image of B0708 fluorescence ( Fig. 2 top row , column 4), shows a diffuse Lysine and arginine residues are highlighted in bold, potential receptor ligand motifs are in bold and underlined. Similar regions are underlined. Apo B100 (CAA28420); Apo E (LPHUE); alpha-2-macrogolublin receptor-associated protein (AMRP P30533, RAP); heat shock protein, HS90B (P08238); endoplasmin (NP_003290); heat shock proteins (AAC02679-HSP75), (AAH09195-HSP90B1), (BAB15121-HSP90), (CAD62296-HSP90), (NP_001017963-HSP90 alpha isoform 1), (NP_005339-HSP90kDa alpha), (NP_055969-MESD); and, TNF receptorassociated protein 1 (AAH18950) signal emitted across the field of view and suggests that signal is located only on the cell surface. There are also several clusters of intense fluorescence; the arrow denotes one of such clusters. An enlargement of the cluster shows that the peptide is on the surface, and not internalized. Clusters appear to be associated with an apoptotic cell. (Table 4) , which includes B0708, does not contain a potential NLS motif, but it does contain stretches/motifs that align well with IRFs 4, 8 and 9. The polar region of IRF 9, EQVESGQ, is conserved to a degree as 0718 HEQDMVNG 0725 in B0708. The proline-glycine dipeptide is absent. Short motifs such as DLKS, EEL-GFASL, LQLLGK, and SKNDFF in B0708 are analogues of motifs EEKS, EEDAALF, AWALFK, and NKSNDF in IRF 4. These similarities are shown and highlighted in Table 4 . DNA binding capacity has not been confirmed experimentally.
Assessment of B2366 HeLa Cell Binding and Entry Capacity
In Fig. 2 (row 3, column 1) , the ×630 overlay image for B2366 shows fluorescence signal dusted over most of the view field. The enlarged region of the image (row 4, column 1) shows signal loci on the membrane perhaps in the cytoplasm. Another enlarged area of the overlay image of B2366 (Fig. 3, row 4 , column 1) shows that signal appears at cell surface, at organelle structures in the cytoplasm, and on extracellular vesicles. Very weak signal emanates from other extracellular debris. There appears to be an increase in extracellular debris, including bleb formation and small vesicles. Signal does not appear to emanate from the nuclear space nor at the nuclear envelope. Table 3 . In addition, B2366 contains motif 2373 VKK, also appearing in sequence 0304-0306 in RAP3d. Overall, apo B100 sequence spanning residues 2110 to 2410 is rich in the receptor ligand motifs of RAP.
Potential Function
Molecular models generated using Phyre 2 suggest that this region has DNA-binding capacity; however, confidence value is low. Ramachandran plot analysis by Rampage software, http://mordr ed.bioc.cam.ac.uk/~rappe r/rampa ge.php, indicates 7.6% of residues are in outlier region, 77.1% in favored region, and 15.3% in allowed region.
Assessment of B2932 Cell Binding and Entry Capacity
Overlay image obtained at ×630 magnification shows high intensity signal across the view field (Fig. 2, rows 3-4 . Column 2). B2932 signal emanates from cell surface as clusters, and endosome formation is suggested (Fig. 3, row 4 , column 3). There is scant extracellular signal. 
B0582 a Potential Proteoglycan/GAG Ligand
Overlay image of B0582 shown in Fig. 2 (top row, 3rd column) was generated with a 173 ms green filter exposure image. B0582 signal appears indiscriminately throughout the view field, i.e. it appears bound to components of the extracellular matrix, cell membrane, cytoplasmic spaces, organelles, including nucleus.
Corresponding enlarged image of the area indicated by red arrow (Fig. 3, row 2 , column 3), shows signal on the cell surface, in the cytoplasm, and at the nuclear envelope. Discrete points of signal appear attached to extracellular debris and associated with apparent cellular material outside the focal plane. Few aggregates are present. Fluorescence images for the shorter peptide B0575 were obtained at 1 s exposure. B0575 signal appears associated predominantly with cells and integrated density of signal per locus and per cell is about 3% and 4%, respectively, of that determined for B0582. Signal area, integrated signal density per locus and per cell ( Lysine and arginine residues are highlighted in bold. Similar residues located in like regions of the sequences are underlined
Comparison of B0582 Sequence and Human Fibroblast Growth Factor 1 GAG Ligand Motif
Apo B100 sequence spanning residues 0573 to 0625, which contains peptides B0575 and B0582, is similar to the heparin-binding site of the human fibroblast growth factor 1 (Table 5 ), but it lacks the "Glycine box" [58] . 
B2054 and Potential RNA Recognition Motifs (RRM) in Apo B100
B2054 image in Fig. 1 shows low density signal that is well dispersed in the view field. Images in Fig. 2 0319 , present in ACF, were used to align both regions of apo B100 with the known RRM domains. Relatively high sequence similarity Table 6 Comparison of potential RNA recognition motifs in apo B100, putative RRM sequences in ApoBEC-1 complementation protein and MSX2-interacting nuclear protein (MINT) . The RNA recognition domain of Msx2-IP binds Runx2 (Runt-related transcription factor 2) to enhance expression of the osteocalcin gene by binding to its control element, the fibroblast growth factor responsive element (OCFRE). Osteocalcin is a non-collagen protein of bone extracellular matrix. Sequence similarity between these proteins and regions in apo B100 suggests a similar function. Regions of high similarity with Site B are underlined. The LRK motif, present in tandem in apo E, and occurs as LKR in the dengue capsid proteins. The RKR motif of apo B100, apo E and Msx2-IP is not identical in the dengue helicases; however, sequence of the region that follows is highly similar to that in apo B100. This similarity is not shared with apo E or the Msx2-IP sequences
B3119 LDL Receptor Ligand Site A is a Potential Procoagulant Inhibitor
Sequence B3119 contains a true Type II ligand, 3149 SKKNKHRH, and is historically known as Site A. This short motif is also a true NLS. B3119 contains two motifs, LKD and LKE, analogues of a receptor ligand motif in RAP, 0190 LKE. Overlay images of B3119 in Fig. 2 (rows 3 and 4 , column 3) show low-level binding on the cell surface and not in the cytoplasm proper. Cell surface aggregates are not apparent. Approximately 7% of cell area in view field binds B3119, forming clusters with relatively high integrated density per locus (Table 2 ). Signal at discrete loci in the extracellular space is significant as seen in original size overlay image (Fig. 2) . These results indicate that Site A in apo B100 may not be a major ligand for an LDL receptor, and perhaps has a different function.
Apo B100 Site A Region as a Procoagulant Inhibitor
Previous reports suggest that this region of apo B100 plays a part in hemostasis as an anticoagulant [63, 64] . Synthetic peptide KRAD-14 spanning residues 3146-3159 of apo B100 (included at the carboxyl end of our peptide B3119), and its mutated form, mutant-4, were shown to inhibit procoagulant activity of tissue factor, 78.5% and 95.5% of Control assay, respectively [63] . The functional motif in the native form is then KAQYKKNKHRHSTT (KRAD-14), which is included in B3119. In mutant-4, functionally important is substitution of lysine in position 5 of the underlined motif with alanine, and sequence KAQSKKNA 5 HRH-STT (mutant-4) appears to be a more effective procoagulation inhibitor. These studies showed that LDL, recombinant peptides of apo B100 spanning 3121 Asp-Thr 3217 (KRAD-98), KRAD-14, and mutant-4 influenced procoagulant activity of tissue factor by preventing Factor VII activation [64] . Peptide KRAD-14 also prevents prothrombin activation by interacting with Factors Xa and V. Hence, the lysine-rich Site A ligand region imparts LDL, and other LLPs, with the capacity to regulate hemostasis.
Sequence Similarity of Apo B100 Site A Region and Known Inhibitors of Coagulation
Further evidence that suggests anticoagulant function for Site A is found in pit viper venom proteins. A comparison of apo B100 sequence spanning residues 3119 to 3170 to snake venom anticoagulant proteins of Deinagkistrodon acutus (1IOD_B), Protobothrops flavoviridis (BAA11888.1), Trimeresurus stejnegeri (Q71RQ9.1 and Q71RR1.1), and Crotalus oregano helleri (AEU60005.1) is shown in Table 7 . The D. acutus anticoagulant B protein binds Factor X and shares several motifs with Site A. Blood factor IX/factor X Binding Protein B chain of P. flavoviridis, contains a C-type lectin (γ-carboxyglutamic acid recognition) GLA-binding sequence, 0121 YFKSTNNKWRS. These residues are highlighted in bold in sequence identified as fIXBP in Table 7 . Analogues occur as MVKKHKENLRTW in snake venom zinc metalloproteinase-disintegrin-like endopeptidases (ADAMS) [65, 66] , and as QYKKNKHRHSITN in apo B100 (a part of Site A). This region of apo B100 shares several motifs with its analogues in pit viper venom proteins, notably LSVK, QYKKN, HRH, SIT, and VLCEFIS. Variations of these motifs appear in other venom proteins as well and are indicated in Table 7 .
B3347-Apo B100 LDL Receptor Ligand Site B
Peptide B3347 that spans residues 3347 to 3389 contains a Type I motif, TRLTRKRGLK that was initially designated as Site B ligand [7, 8, 19] . B3347 peptide displays low binding avidity, and signal appears on cell surface and in the extracellular spaces. A labeled synthetic peptide of Site B was shown to bind heparin and dextran sulfate cellulose; hence, this region may bind GAGs and highly sulfated proteoglycans [43] .
Comparison of B3347 sequence to the established LDLR ligand sequence in apo E and similar sequences in unrelated proteins is shown in Table 8 . In apo E, lysine residues in positions 0143 and 0146 (KXXK) are critical in binding LA modules 4 and 5 of the LDLR [32] and are in a Type I motif. Although Site B of B100 and the other proteins listed in Table 8 contain a Type I receptor ligand motif, the lysine residues in equivalent positions are not conserved. The slight difference between Site B in apo B100 (hence, in B3347) and the apo E ligand sequence is reflected by their significant difference in cell binding.
Control Assays-Influence of PBS, 10% FBS, and 3% FBS-Mevastatin
Three sets of control cell binding assays were included to distinguish between receptor and non-receptor binding for peptides B0582, B3181, B2366, B3119 (Site A), and B3347 (Site B). Cells were propagated in six well trays as described in Sect. 2. One set of trays was pre-conditioned in 3% FBS-DMEM plus mevastatin and two sets were maintained in 10% FBS-DMEM less mevastatin. Mevastatin is known to cause upregulation of LDL receptors [47, 48] . Cultures were rinsed thrice with PBS then incubated in 3% FBS-DMEM + B peptide (for mevastatin-treated cells only), and 10% FBS-DMEM + B peptide or PBS + B peptide. Results shown in Table 9 are based on average values obtained from 3 to 4 different view fields processed using ImageJ as described in Sect. 2.
B0582 Control Assays
Values for Total Loci/cell and % signal area seen in FBScontaining assays are approximately 3.7 and 2.5 times higher (respectively) in mevastatin-treated versus untreated cells. PBS alone assays show substantial increase in % signal area (approximately 6.5 and 16.6-fold increase compared to mevastatin-treated and untreated cells, respectively). B0582 is similar to the heparin binding region of FGF1; however, it also contains three potential LDL receptor ligand motifs, LKK, VKE, and LKE, analogues of receptor ligand motifs in RAP. Hence, both properties, GAG-binding and Receptor binding motifs, may contribute to binding in these assays. Pre-treatment with mevastatin may enhance binding via the proposed receptor ligand motifs in the sequence.
B3181 Control Assays
In assays with FBS, the total loci number and the % signal area per cell are substantially (approximately four times) higher in mevastatin-treated cells. In absence of mevastatin treatment, these values are approximately 1.8-2.1 times higher in PBS alone assays compared to 10% FBS assays. B3181 is a lysine-rich sequence that contains three RAP-like ligand motifs and one Type III motif. Cell binding characteristics observed for B3181 in the 3% FBS-mevastatin assays are the highest values obtained with other B peptides used in these control studies. Strong influence of mevastatin treatment on B3181 binding suggests involvement of the LDL or related receptors interaction of this peptide with the cells.
B2366 Control Assays
Treatment of cells with mevastatin enhances binding of peptide B2366 in FBS-containing assays (approximately fourand two-fold, using the % area and the number of loci per cell, respectively). This peptide contains RAP-like receptor ligands motifs, VKK and LKK, and binds HeLa cells in 3% FBS-mevastatin and PBS media almost as well as B3181. The data suggest involvement of LDL receptor in interaction of this peptide with the cells.
B3119 Control Assays
The effect of mevastatin on binding of B3119 (site A) was not significant. Values for FITC loci per cell, % signal area and IDS per cell are only slightly higher in the mevastatintreated cells compared to PBS alone assays.
B3347 Control Assays
Treatment with mevastatin enhances binding of B3347 (2.0-and 2.2-fold increase in loci number per cell and % signal area, respectively, compared to untreated cells), however, the integrated signal density per cell does not change significantly. This peptide contains a Type I receptor/GAG binding motif but lacks motifs present in the receptor ligand region of apo E or any rendition of a RAP receptor ligand.
Influence of E2 Synthetic Peptide on Binding and Internalization of B-Peptides
The LDL receptor-related protein gene family is vast. Each member protein contains multiple ligand adhesion modules (LA), also complement-type repeats. The ligand moiety in apo E binds ligand modules 3-5 of LDLR [67] while apo B100 putatively binds LRs 3, 4, 5, 6 and perhaps 7 of the LDLR [68] . HeLa cell assays were used to assess qualitatively the influence of unlabeled synthetic E2 peptide on binding of apo B peptides. E2 peptide spans residues 0129
Ser-Gly 0165 of apolipoprotein E and includes two in tandem copies of LRK, an analogue of RAP motif 0304 VKK. In these experiments, the 500 µL cell-binding assay was prepared using 15 µg of E2 peptide, and 10 µg of apo B peptide in PBS with 5 mM MgCl 2 . Control assays without E2 were included for each apo B peptide. Cells were incubated, washed, fixed and images were obtained as described in Sect. 2. Images were subjected to analysis using ImageJ as before. Bright field and fluorescence overlay images in Fig. 3 show results obtained in assays that included E2 with peptides all peptides listed in Table 1 except for B3181 (depleted supply).
E2 Peptide and B0013-FITC Peptide HeLa Cell Interaction
B0013 contains on analogue of the RAP receptor ligand motif VKK as LRK identical to that in E2 which contains two copies; hence, the unlabeled E2 and B0013 molar ratio is approximately 3 to 1. Addition of E2 peptide reduced the number of signal emitting sites by 70%, while total area of signal was only reduced by ~ 9%, average size of area emitting signal and integrated density were correspondingly increased by 3.2 fold. In both assays signal appears to be in clusters and on the cell surface.
E2 Peptide and B0055-FITC Peptide HeLa Cell Interaction
Addition of E2 to assays with B0055-FITC increased the number of sites emitting signal by approximately 2.7 and total area of signal by 4.4 fold while total integrated density was increased by only 5%. In both overlay images shown in Fig. 3 , FITC signal appears to be on the cell surface and the presence of E2 appears to increase the size of the clusters but not the intensity of signal.
E2 Peptide and B0575-FITC Peptide HeLa Cell Interaction
Peptide B0575 includes three analogues of RAP receptor ligand motifs. Although E2 peptide increases the number of sites emitting B0575 signal sixfold, the average locus size and total integrated density values were deceased by 86%. The images in Fig. 3 show that in both assays the signal appears on the cell surface.
E2 Peptide and B0582-FITC Peptide HeLa Cell INTERACTION
Fluorescence images of B0582, which includes B0575 receptor ligand analogue motifs and a potential endocytic motif as FRKF, show a relatively high background on the extracellular matrix, signal is also emitted from the cell surface and in the cytoplasmic space. These are characteristic in images of B0582 and B0582 E2. E2 increased the number of fluorescence loci threefold on B0582 alone and the average size of the loci and integrated density values in B0582 E2 assay are about 33% of the B0582 assay. Hence, E2 appears to compete with both B0575 and B0582. LKS that are analogues of motifs in RAP, but this apo B sequence does not appear to contain a functional endocytic motif. Although E2 does not increase binding of B0708, its presence mediates endocytosis. In Fig. 3 , B0708 E2 frame, signal is seen in the extracellular space at discrete loci, on the cell surface, in the cytoplasm, and perinuclear.
E2 Peptide and B2054-FITC Peptide HeLa Cell Interaction
Potential receptor ligand motifs LKH and VRK are in B2054. This is low binding peptide covering only about 0.1% of the total area; E2 reduces this value by 70%. Average size and integrated density of loci are reduced by 77%. E2 does not appear to enhance cell entry for B2054.
E2 Peptide and B2366-FITC Peptide HeLa Cell Interaction
B2366 is replete with two RAP receptor ligand, VKK and IKK, and several types of endocytic motifs. Addition of E2 enhances binding, uptake and intracellular distribution of the signal changes substantially (Fig. 3) . Concomitantly, signal loci and total area of signal are slightly reduced by 15% and 5%, respectively; while the average size of loci and integrated density are increased by 10%. In a representative overlay image B2366 E2 shows signal from apparent cell surface, in endosome-like structures in the cytoplasm and periphery of the nucleus, and in the nucleus. A trace of FITC signal appears associated with extracellular materials.
E2 Peptide and B2932-FITC Peptide HeLa Cell Interaction
B2932 contains motif 2937 SKHLRV, an analogue of B0013 motif, 0018 FKHLRK (see Table 1 ). Three renditions of the KHL motif occur in RAP. In the control assay, B2932 overlay, discrete microvesicle-like structures are seen in the extracellular space. B2932 E2 overlay also shows signal emanating from extracellular regions. Interestingly, approximately 30% of cells emitting signal in the related ×630 magnification view field of the B2932 E2 overlay appear to be undergoing apoptosis, two are seen at the upper left corner of the corresponding frame in Fig. 3 . This effect was not evident in B2932 alone assays. B2932 E2 frame also shows intense signal associated with what may be the nucleolus and chromatin, and appears as spheres at the nuclear envelope. E2 reduced the number of signal loci by half. Total area emitting signal and integrated density values were increased by 81%.
E2 Peptide and B3119-FITC Peptide HeLa Cell Interaction
E2 increased integrated density of signal in the view field of B3119 as about 8.9 fold. B3119 overlay in Fig. 3 shows signal in the cell cytoplasm in discrete endosome-like structures, with a few located at the nuclear periphery. Addition of E2 peptide enhanced intracellular uptake and altered discrete site distribution with vibrant signal in cytoplasm, organelles, and in the nucleus appears associated with chromatin and nucleolus. B3119 E2 frame also shows signal emanating from vesicles in the extracellular space.
E2 Peptide and B3347-FITC Peptide HeLa Cell Interaction
In Fig. 3 frames for B3347 and B3347 E2 show that E2 appears to influence binding of B3347 to HeLa cells but cell entry is not discernable in either frame. E2 increases number of signal loci by 8.6 fold and total signal area by almost twofold. Average size of loci and integrated density values are decreased 78%. B3347 peptide lacks a legitimate RAP receptor ligand; however, it contains a Cardin-Weintraub Type I GAG binding motif [32, 33] . It is possible that E2 opens an increased number of receptors providing more sites for B3347 binding. Another consideration is that motifs YKL, TRK, and NKF are actually weak binding ligands. Results for B3181, B3119 and B3347 are shown as triple image overlays, bright field on FITC on CM-DiI, in Fig. 6 . These peptides showed low binding capacity with few sites emanating signal. In Frame B3181 signal appears as large, discrete aggregates (red arrows) on the cell surface and as endosome-like structures in the cytoplasm as seen also in Fig. 2 . Co-location of B3181 and LDL signals is seen at few sites and appears to be only outside the cell. B3119 peptide also appears in large, high intensity signal aggregates alone as well as co-located with LDL signal. The LDL signal emanates from the majority of the cells in the view field while B3119 signal is not. Signal for B3347 appears in a few high density aggregates and small discrete points on the cell surface and in a few instances also appears to be in the cytoplasm. There is a trace of signal for this peptide in the extracellular spaces. LDL signal is throughout the view field on the cell surface, in the cytoplasm and outside the cell proper. Red arrows indicate co-localized signals in the three frames of Fig. 6 .
Co
Discussion
Hydrophilic synthetic peptides of regions in apoB100 sequence are useful in establishing its potential functional domains. Our initial aim was to identify the regions in apo B100 that impart receptor binding capacity to the LDL particles. The apo B100 sequence contains 148 arginine residues and 356 lysine residues, roughly 11% of the molecule. All peptides used in the present study are rich in basic amino acids and therefore all bind non-specifically to dextran sulfate cellulose beads. Arginine residues bind 2.5× more tightly to GAGs than lysine [34] . In apo E, lysines in positions 143 and 146 are critical residues for high affinity binding to LDL B/E receptor [35, 36] . Previously, Cardin-Weintraub ligand motifs were used to identify potential GAG/receptor ligands [32] [33] [34] [7, 8, 18, 19, 42] . Peptides obtained using proteolytic digestion showed two sites, 3134 Leu-Lys 3209 and 3356 Thr-Ala 3489 , with high binding affinity for heparin; and, hence, were considered to possess LDL receptor binding capacity also [33] . A separate study showed that four murine monoclonal antibodies, Mabs 2A, 5A, 7A, and 9A, to epitopes at three different regions in apo B100, reduced LDL interaction with the receptor by "up to 95%" [44] . These apo B100 regions are defined as follows: 5A, 1480 , Mab 9A epitope, includes our peptides B2932, B3119 and B3181. Therefore, our findings indirectly support the results of the Mabs study. A major drawback is that the monoclonal antibody "footprint", i.e. molecular size, may obscure the actual ligand site residues that are remote to the epitope.
Proposed Receptor Binding Regions in Apo B100
Six short stretches of the apo B100 sequence, B0013, B0582, B0708, B2366, B2932 and B3181, bind HeLa cells with high affinity. The sequence comparison in Table 3 shows many similar motifs and short sequences shared between these stretches of apo B100 and RAP. RAP is an ER resident chaperone protein that is involved in the proper intracellular folding of the LDL receptor and related proteins [69] . RAP putatively binds to all members of the LDL receptor family [55] . RAP is comprised of 357 amino acids in three distinct, 100-residue domains. Each domain contains three helical structures. Three residue lysine-based motifs, e.g. DKL, EKH and VKK, in RAP that are involved in binding ligand adhesion modules, are common in apo B100. Different renditions of the polar sequence, 0024 YTYNYEAESSS in apo B100, are also in apo E2 peptide, RAP and the DNAbinding domains of the IRF proteins. Effects of E2 peptide, containing known receptor ligands, on B peptides interaction with HeLa cells, both competition and enhancement of binding, support presence of functional receptor ligand motifs in the B peptides.
Four regions in apo B100, residues 0013-0094, 0705-0805, 2932-3031 and 3120-3216, may also function as nucleic acid binding domains. Each region contains motifs that are present in the DNA binding domain of the IRF proteins. Previously, highly purified LDL was shown to bind plasmid DNA and RNA [25] , and DNA binding capacity for the N-terminal region of apo B100 was confirmed experimentally using synthetic peptides for this region [26] .
Apo B100 sequence also contains 11 K homology (KH) modules typical in RNA-binding proteins including vigilin (Q00341), which are identified by motif GXXG. Herein, we identify two other regions that appear to be RNA Recognition Motifs based on the similarity of the amino-and carboxyl-termini of known RRM domains in MINT and apoBEC-1 complementation factor.
Potential Anticoagulant Function of Apo B100
Site A, KAQYKKNKHRHSITN Anticoagulant function for this region of apo B100 was proposed previously by Ettelaie et al. [63, 64] . Those studies showed that a synthetic peptide spanning apo B100 region 3146 Lys-and Thr 3160 inhibits tissue factor-factor VII/VIIa procoagulant activity. Peptide KRAD-14 and mutant 4 [63] were shown to inhibit procoagulant activity by 98-99% and suggest "KKN" and "HRHS" as essential motifs in the process. Analogues of both motifs are present in snake venom Blood Factors IX and X binding proteins and in ADAMS proteins that are associated with hemorrhagic phenomena. We surmise that upon injury to the arterial wall and/ or endothelium, neutrophils and keratinocytes release elastase, which cleaves the molecule at Val 3145 
What is the Actual Function of Apo B100 Site B, TRKRGLKL?
Apo B100 sequence spanning 3347 Asp-Lys 3366 is highly similar to apo E receptor ligand sequence 0131 Glu-Arg 0150 , both sequences contain a Type I ligand motif. Reproducible experimental evidence indicates that Site B100 is not the preferred ligand for the receptors in HeLa cells. The comparison of these sequences in Table 8 reveals two differences that suggest different functions. Apo E contains two copies of the motif LRK in tandem. Site B lacks this motif and does not contain any of the other lysine-based ligand motifs present in RAP. The apo B100 sequence that follows, 3367 Leu-Val 3378 , is significantly different from 0151 Asp-Tyr 0163 that trails the receptor ligand sequence in apo E, and is more similar to the sequence, 1692 Leu-Glu 1706 of the NS3 helicase region of the dengue polyprotein (BAD42414). This difference in primary structure suggests a difference in the secondary structure of Site B region, i.e. this segment is part of an amphipathic helix in apo E but is a β-strand in the dengue [70] . Synthetic peptides that include Site B were previously shown to bind plasmid DNA [26] . These observations suggest this apo B100 region may function as a helicase. The RKR motif of apo B100 Site B is also contained twice in MINT, a DNA-binding protein, and twice in dengue 1 polyprotein, at the Carboxyl-termini of the capsid protein and NS3 peptidase region. This motif may also indicate a separate function in both dengue and apo B100. It also occurs at the N-terminal region of human intermediate conductance calcium-activated potassium channel, hIK1 (AAC23541), and plays a role in its function [71] . The RKR motif, located at the C-terminus of the ATP-sensitive inward rectifier potassium channel 11 (KCJ11_HUMAN), is an ER localization signal that prevents ER exit of unassembled membrane protein complexes [72] . Also, intriguing is the potential that RKR and related analogues, KKK, KRK, and RKR in apo B100, and carboxyl-terminal KKXX motifs, two occur in apo B100 at positions 4457 and 4512, are intracellular signaling motifs, i.e., endoplasmic reticulum localization signals [73] . These motifs function in partitioning of proteins to designated subcellular compartments [74] .
Are Apo B100 lipoparticles involved in the immune response?
Apo B100 is a member of the LLTP superfamily, which includes vitellogenin-like LLTPs, vigilin, MTTPs [9, 10] , and insect apolipophorins [11, 12] . LLTP molecules are involved in extracellular transport of hydrophobic lipids and triglycerides [9, 10] , binding nucleic acids [15] [16] [17] , and appear to be involved in the immune response [12] [13] [14] . LLTPs, including apo B100, share a common ancestor [9] and therefore contain similar primary structures that impart similar functions. For example, Vigilin contains 13 K-homology nucleic acid binding domains as compared to 11 similar sequences in apo B100, both molecules have been shown to bind RNA [15] [16] [17] 25] . VTG A2 also contains 10 K-homology RNA binding motifs. K-homology nucleic acid binding domains are characterized by the "GXXG" motif. A motif contained in vitellogenin, vigilin and apo B100 is "GXXGXG", 0680 IEIGIRGEGIE,
0986
YVIGQKGS-GIR, and 0660 IEIGLEGKGFE, respectively. There is also significant sequence similarity of N-termini of apo B100, vitellogenin and the DNA-binding domains of the IRF proteins. The N-terminal sequence of vitellogenin-A2, VTG A2, is compared to the DNA-binding domains of the IRF proteins and the N-terminal region of apo B100 in Table 4 . These observations support the concept that LLTPs play a role in the immune response.
Apo B100 is likely a component of a circulating acutephase response mechanism, an element of an emergency control and repair unit/package, always ready on site to address any injury/assault to the tissue. A multi-functional apo B100 may work in concert with apo E, and other "riders" lipids, phospholipids, cholesterol, steroids, vitamins, and other metabolites necessary to maintain the integrity of the organism by repairing tissue, removing foreign matter, and alerting the immune system. We speculate that lipids, phospholipids and cholesterol may facilitate tertiary structural transformation of apo B100 into a conformation necessary to address a specific need. We surmise that upon injury endopeptidases present on site and/or secreted by keratinocytes and neutrophils may release functional regions of apo B100.
